Compare CYD & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYD | COLL |
|---|---|---|
| Founded | 1951 | 2002 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1998 | 2015 |
| Metric | CYD | COLL |
|---|---|---|
| Price | $28.30 | $21.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $59.10 | $49.00 |
| AVG Volume (30 Days) | 122.9K | ★ 791.1K |
| Earning Date | 08-07-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $13.33 | $7.09 |
| Revenue Next Year | $9.34 | $1.31 |
| P/E Ratio | $32.71 | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $28.65 | $21.43 |
| 52 Week High | $61.48 | $50.79 |
| Indicator | CYD | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 27.60 | 28.89 |
| Support Level | N/A | $21.65 |
| Resistance Level | $45.94 | $23.69 |
| Average True Range (ATR) | 1.64 | 0.82 |
| MACD | -0.07 | 0.22 |
| Stochastic Oscillator | 2.08 | 19.91 |
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.